Compare QNRX & AMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QNRX | AMS |
|---|---|---|
| Founded | 2018 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 13.9M |
| IPO Year | 2023 | 1995 |
| Metric | QNRX | AMS |
|---|---|---|
| Price | $8.69 | $2.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 24.4K | 8.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 230.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,714,000.00 |
| Revenue This Year | N/A | $3.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.81 |
| 52 Week Low | $0.21 | $2.02 |
| 52 Week High | $41.80 | $3.11 |
| Indicator | QNRX | AMS |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 44.16 |
| Support Level | $8.03 | $2.04 |
| Resistance Level | $10.05 | $2.19 |
| Average True Range (ATR) | 0.80 | 0.08 |
| MACD | 0.20 | -0.01 |
| Stochastic Oscillator | 47.73 | 8.06 |
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.